Charles River (NYSE: CRL) CFO receives 21,112-share stock award

Rhea-AI Filing Summary

Coleman Glenn reported acquisition or exercise transactions in this Form 4 filing.

Charles River Laboratories International EVP & Chief Financial Officer Glenn Coleman received an equity grant of 21,112 shares of Common Stock on May 1, 2026. The grant was reported at $165.78 per share, and following this award he directly owns 21,112 shares.

According to the filing footnote, these unvested restricted stock units are scheduled to vest in equal annual installments on May 1, 2027, May 1, 2028, May 1, 2029, and May 1, 2030, tying the award to multi‑year service and performance with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Coleman Glenn

Role EVP & Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	21,112	$165.78	$3.50M

Holdings After Transaction: Common Stock — 21,112 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Equity grant size: 21,112 shares Grant reference price: $165.78 per share Holdings after transaction: 21,112 shares

3 metrics

Equity grant size 21,112 shares Common Stock award to CFO on May 1, 2026

Grant reference price $165.78 per share Reported price for the 21,112-share award

Holdings after transaction 21,112 shares Total Common Stock directly owned by CFO after grant

Key Terms

restricted stock units, Grant, award, or other acquisition, Common Stock

3 terms

restricted stock units financial

"Unvested restricted stock units annually ratably vest on: May 1, 2027; May 1, 2028; May 1, 2029; and May 1, 2030."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coleman Glenn

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE ST

(Street)

WILMINGTON MASSACHUSETTS 01887

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		A		21,112(1)	A	$165.78	21,112	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Unvested restricted stock units annually ratably vest on: May 1, 2027; May 1, 2028; May 1, 2029; and May 1, 2030.

	/s/ Glenn Coleman	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CRL CFO Glenn Coleman report on this Form 4?

Glenn Coleman reported receiving a grant of 21,112 shares of Charles River Laboratories Common Stock. The award was reported at $165.78 per share and represents a compensation-related equity grant rather than an open-market stock purchase or sale.

How many CRL shares does the CFO hold after this reported equity grant?

After the reported transaction, Glenn Coleman holds 21,112 shares of Charles River Laboratories Common Stock directly. This entire position reflects the new grant disclosed in the filing, with no additional purchases or sales reported in this Form 4.

How do the CRL restricted stock units granted to the CFO vest over time?

The unvested restricted stock units vest annually in equal parts on May 1, 2027, May 1, 2028, May 1, 2029, and May 1, 2030. This schedule spreads the award over four years, encouraging ongoing executive retention and alignment with shareholder interests.

Was the CRL CFO’s reported transaction an open-market buy or a stock award?

The transaction is classified as a grant or award acquisition, not an open-market buy. The Form 4 uses transaction code “A” and describes it as a grant of 21,112 shares, reflecting equity compensation rather than a discretionary market purchase by the executive.

What role does Glenn Coleman hold at Charles River Laboratories (CRL)?

Glenn Coleman is Executive Vice President and Chief Financial Officer of Charles River Laboratories International. The reported stock grant aligns his compensation with company performance, as the award vests in stages from 2027 through 2030 according to the disclosed vesting schedule.